These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 28837373)

  • 21. Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).
    Loibl S; de la Pena L; Nekljudova V; Zardavas D; Michiels S; Denkert C; Rezai M; Bermejo B; Untch M; Lee SC; Turri S; Urban P; Kümmel S; Steger G; Gombos A; Lux M; Piccart MJ; Von Minckwitz G; Baselga J; Loi S
    Eur J Cancer; 2017 Nov; 85():133-145. PubMed ID: 28923573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
    Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
    Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Di Leo A; Johnston S; Lee KS; Ciruelos E; Lønning PE; Janni W; O'Regan R; Mouret-Reynier MA; Kalev D; Egle D; Csőszi T; Bordonaro R; Decker T; Tjan-Heijnen VCG; Blau S; Schirone A; Weber D; El-Hashimy M; Dharan B; Sellami D; Bachelot T
    Lancet Oncol; 2018 Jan; 19(1):87-100. PubMed ID: 29223745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patients' reasoning regarding the decision to participate in clinical cancer trials: an interview study.
    Dellson P; Nilsson K; Jernström H; Carlsson C
    Trials; 2018 Sep; 19(1):528. PubMed ID: 30268150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy.
    Nurgat ZA; Craig W; Campbell NC; Bissett JD; Cassidy J; Nicolson MC
    Br J Cancer; 2005 Mar; 92(6):1001-5. PubMed ID: 15770219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Parents' and children's comprehension and decision in a paediatric early phase oncology trial: a prospective study.
    Béranger A; Bouazza N; de Haut de Sigy A; Foubert-Wenc AC; Davous D; Aerts I; Geoerger B; Auvrignon A; Brethon B; Leblond P; Corradini N; André N; Martinez H; Dupont JK; Doz F; Chappuy H
    Arch Dis Child; 2019 Oct; 104(10):947-952. PubMed ID: 30472665
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy.
    Pistilli B; Pluard T; Urruticoechea A; Farci D; Kong A; Bachelot T; Chan S; Han HS; Jerusalem G; Urban P; Robinson D; Mouhaër SL; Tomaso ED; Massacesi C; Saura C
    Breast Cancer Res Treat; 2018 Apr; 168(2):357-364. PubMed ID: 29198055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.
    Garrido-Castro AC; Saura C; Barroso-Sousa R; Guo H; Ciruelos E; Bermejo B; Gavilá J; Serra V; Prat A; Paré L; Céliz P; Villagrasa P; Li Y; Savoie J; Xu Z; Arteaga CL; Krop IE; Solit DB; Mills GB; Cantley LC; Winer EP; Lin NU; Rodon J
    Breast Cancer Res; 2020 Nov; 22(1):120. PubMed ID: 33138866
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Communication about the risks and benefits of phase I pediatric oncology trials.
    Hazen RA; Zyzanski S; Baker JN; Drotar D; Kodish E
    Contemp Clin Trials; 2015 Mar; 41():139-45. PubMed ID: 25638751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
    Schouten PC; Dackus GM; Marchetti S; van Tinteren H; Sonke GS; Schellens JH; Linn SC
    Trials; 2016 Jun; 17(1):293. PubMed ID: 27323902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
    Zielinski C; Láng I; Inbar M; Kahán Z; Greil R; Beslija S; Stemmer SM; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Petruzelka L; Eniu A; Nisenbaum B; Dank M; Anghel R; Messinger D; Brodowicz T;
    Lancet Oncol; 2016 Sep; 17(9):1230-9. PubMed ID: 27501767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of the Perceived Acceptability of an Early Enrollment Strategy Using Advance Consent in Health Care-Associated Pneumonia.
    Corneli A; Perry B; Collyar D; Powers JH; Farley JJ; Calvert SB; Santiago J; Donnelly HK; Swezey T; Dombeck CB; De Anda C; Fowler VG; Holland TL
    JAMA Netw Open; 2018 Dec; 1(8):e185816. PubMed ID: 30646295
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Motivations of children and their parents to participate in drug research: a systematic review.
    Tromp K; Zwaan CM; van de Vathorst S
    Eur J Pediatr; 2016 May; 175(5):599-612. PubMed ID: 27041121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Deliberating clinical research with cognitively impaired older people and their relatives: an ethical add-on study to the protocol "Effects of Temporary Discontinuation of Antihypertensive Treatment in the Elderly (DANTE) with Cognitive Impairment".
    van Rookhuijzen AE; Touwen DP; de Ruijter W; Engberts DP; van der Mast RC
    Am J Geriatr Psychiatry; 2014 Nov; 22(11):1233-40. PubMed ID: 23973250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Study of the media's potential influence on prospective research participants' understanding of and motivations for participation in a high-profile phase I trial.
    Pentz RD; Flamm AL; Sugarman J; Cohen MZ; Daniel Ayers G; Herbst RS; Abbruzzese JL
    J Clin Oncol; 2002 Sep; 20(18):3785-91. PubMed ID: 12228198
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Healthy volunteers' perceptions of risk in US Phase I clinical trials: A mixed-methods study.
    Fisher JA; McManus L; Cottingham MD; Kalbaugh JM; Wood MM; Monahan T; Walker RL
    PLoS Med; 2018 Nov; 15(11):e1002698. PubMed ID: 30457992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigating the informed consent process, therapeutic misconception and motivations of Egyptian research participants: a qualitative pilot study.
    Mansour H; Zaki N; Abdelhai R; Sabry N; Silverman H; El-Kamary SS
    East Mediterr Health J; 2015 May; 21(3):155-63. PubMed ID: 26074215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
    Mayer IA; Abramson VG; Isakoff SJ; Forero A; Balko JM; Kuba MG; Sanders ME; Yap JT; Van den Abbeele AD; Li Y; Cantley LC; Winer E; Arteaga CL
    J Clin Oncol; 2014 Apr; 32(12):1202-9. PubMed ID: 24663045
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Research participants' high expectations of benefit in early-phase oncology trials: are we asking the right question?
    Weinfurt KP; Seils DM; Lin L; Sulmasy DP; Astrow AB; Hurwitz HI; Cohen RB; Meropol NJ
    J Clin Oncol; 2012 Dec; 30(35):4396-400. PubMed ID: 23091107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.